Top Story

FDA approves Opdivo for treatment of advanced melanoma

December 22, 2014

The U.S. Food and Drug Administration has granted accelerated approval to Opdivo as treatment for patients with unresectable and metastatic melanoma who no longer respond to other drugs, according to a press release.

Opdivo (nivolumab, Bristol-Myers Squibb) inhibits the PD-1 protein on cells, which blocks the body’s immune system for attacking melanoma tumors, according to the release. It is indicated for patients with melanoma previously treated with Yervoy (ipilimumab, Bristol-Myers Squib), as well as for those whose tumors express the gene mutation BRAF V600 after treatment with ipilimumab and a BRAF inhibitor.

In the Journals

Men, older patients made up majority of NMSC diagnoses during routine skin exams

December 22, 2014
Nonmelanoma skin cancer was diagnosed in approximately 7% of patients presenting for routine dermatologic examination, with the majority being men and those older than…
FDA News

FDA grants orphan drug designation to pancreatic cancer treatment

December 22, 2014
The FDA granted orphan drug designation to a pancreatic cancer treatment in development by Nuvilex Inc., the company announced today.The targeted chemotherapy treatment…
In the Journals

Nitrogenous bisphosphonate use may reduce risk for endometrial cancer

December 22, 2014
Exposure to nitrogenous bisphosphonates appeared to have a protective effect on the incidence of endometrial cancer in women who never had the malignancy, according to…
Meeting News Coverage

Extended anticoagulation reduced risk for recurrent VTE, major bleeding

December 22, 2014
SAN FRANCISCO — Patients who experienced unprovoked pulmonary embolism had a significant reduction in the composite risk for recurrent venous thromboembolism and…
More News Headlines »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Vosaroxin combination demonstrated improved survival in AML

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of…
More »
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »